Abstract
Ifenprodil is a novel N-methyl-D-aspartate (NMDA) receptor antagonist that selectively inhibits receptors containing the NR2B subunit. As such, it has become widely used as a tool to study subtypes of NMDA receptors both in vitro and in vivo, and as a tool for molecular studies of the properties and regulation of NMDA receptors. Ifenprodil has an unusual form of activity-dependence and its mechanism of action may involve an increase in proton inhibition of NMDA receptors. These properties are shared by analogs or derivatives of ifenprodil, some of which may be lead compounds for therapeutically useful NMDA antagonists. Such antagonists have potential as neuroprotectants, anticonvulsants, analgesics, and for the treatment of Parkinsons disease and other disorders of the nervous system. The location of the ifenprodil binding site on NMDA receptors and the structural and mechanistic basis of its effects are still unknown. Recent work suggests that at least part of the ifenprodil binding site is located in the R1 / R2 domain of the NR1 subunit. This region, like the S1 / S2 agonist binding domain, shares homology with bacterial periplasmic binding proteins.
Keywords: NMDA Receptor Antagonist, ifenprodil binding site, MK-801, NR1/NR2 receptors, Proton Inhibition, glycine-independent stimulation, leucine isoleucine valine binding protein (LIVBP)
Current Drug Targets
Title: Ifenprodil, a Novel NMDA Receptor Antagonist : Site and Mechanism of Action
Volume: 2 Issue: 3
Author(s): Keith Williams
Affiliation:
Keywords: NMDA Receptor Antagonist, ifenprodil binding site, MK-801, NR1/NR2 receptors, Proton Inhibition, glycine-independent stimulation, leucine isoleucine valine binding protein (LIVBP)
Abstract: Ifenprodil is a novel N-methyl-D-aspartate (NMDA) receptor antagonist that selectively inhibits receptors containing the NR2B subunit. As such, it has become widely used as a tool to study subtypes of NMDA receptors both in vitro and in vivo, and as a tool for molecular studies of the properties and regulation of NMDA receptors. Ifenprodil has an unusual form of activity-dependence and its mechanism of action may involve an increase in proton inhibition of NMDA receptors. These properties are shared by analogs or derivatives of ifenprodil, some of which may be lead compounds for therapeutically useful NMDA antagonists. Such antagonists have potential as neuroprotectants, anticonvulsants, analgesics, and for the treatment of Parkinsons disease and other disorders of the nervous system. The location of the ifenprodil binding site on NMDA receptors and the structural and mechanistic basis of its effects are still unknown. Recent work suggests that at least part of the ifenprodil binding site is located in the R1 / R2 domain of the NR1 subunit. This region, like the S1 / S2 agonist binding domain, shares homology with bacterial periplasmic binding proteins.
Export Options
About this article
Cite this article as:
Williams Keith, Ifenprodil, a Novel NMDA Receptor Antagonist : Site and Mechanism of Action, Current Drug Targets 2001; 2 (3) . https://dx.doi.org/10.2174/1389450013348489
DOI https://dx.doi.org/10.2174/1389450013348489 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers
Current Alzheimer Research Structure-Activity Relationships for Serotonin Transporter and Dopamine Receptor Selectivity
Medicinal Chemistry Editorial [Hot Topic: Glutamate Receptors and Related Processes as Drug Targets (Guest Editor: Michel Baudry)]
Current Drug Targets GABAergic Pharmacotherapy in the Treatment of Motor Disorders of the Central Nervous System
Current Pharmaceutical Design Approaches to Mitochondrial Gene Therapy
Current Gene Therapy Editorial [Hot Topic: Ion Channels: Applications in Ion Channel Drug Discovery(Guest Editor: Douglas S. Krafte)]
Combinatorial Chemistry & High Throughput Screening Topiramate: Its Pharmacological Properties and Therapeutic Efficacy in Epilepsy
Mini-Reviews in Medicinal Chemistry Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued) Curcumin as an Adjuvant to Breast Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Familial Mediterranean Fever
Current Rheumatology Reviews Ketamine: New Indications for an Old Drug
Current Drug Targets Controlled Parenteral Formulations: An Efficacious and Favourable Way to Deliver the Anti-psychotic Drugs
Current Psychiatry Research and Reviews Dangerous Liaisons: Tau Interaction with Muscarinic Receptors
Current Alzheimer Research Modulators of Nucleoside Metabolism in the Therapy of Brain Diseases
Current Topics in Medicinal Chemistry Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis
CNS & Neurological Disorders - Drug Targets Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls
Current Psychiatry Reviews TRP Channels: New Potential Therapeutic Approaches in CNS Neuropathies
CNS & Neurological Disorders - Drug Targets Inhibition of Opioid Receptor Mediated G-Protein Activity After Chronic Administration of Kynurenic Acid and its Derivative without Direct Binding to Opioid Receptors
CNS & Neurological Disorders - Drug Targets Nicotinic Acetylcholine Receptor Interaction with β -Amyloid: Molecular, Cellular, and Physiological Consequences
Current Alzheimer Research Drugs Treatment of Pain in Multiple Sclerosis
Current Clinical Pharmacology